

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

#### **(1) POSTPONEMENT OF THE ANNUAL GENERAL MEETING; AND (2) CONTINUED SUSPENSION OF TRADING**

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 1 August 2018, 25 March 2024, 2 April 2024, 18 April 2024, 5 June 2024 (collectively the “**Announcements**”) pursuant to, among other things, Rules 13.09(2)(a), 13.46(2) and 13.49(1) of the Rules (the “**Listing Rules**”) governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

#### **POSTPONEMENT OF THE ANNUAL GENERAL MEETING**

As a result of the delay in publication of the 2023 Annual Results and the 2023 Annual Report, which is expected to be completed by the end of July 2024, and having considered the requirements under the applicable rules and the articles of association of the Company (the “**Articles of Association**”), it is expected that the convening of the annual general meeting of the Company will be postponed.

Pursuant to Rule 13.46(2)(b) of the Listing Rules, the Company should lay its annual financial statements before its shareholders at its annual general meeting within the period of six months after the end of the financial year or accounting reference period to which the annual financial statements relate (i.e., on or before 30 June 2024).

Pursuant to Article 62 of the Articles of Association, an annual general meeting of the Company shall be held within six months after the end of the Company’s financial year (i.e., on or before 30 June 2024).

Following the delay in publication of the 2023 Annual Results and the 2023 Annual Report, it is expected that the convening of the annual general meeting of the Company will be postponed beyond six months from the financial year end date of 31 December 2023. The postponement of the annual general meeting of the Company will constitute a non-compliance with Rule 13.46(2)(b) of the Listing Rules and Article 62 of the Articles of Association.

The Company will publish further announcement(s) to inform its Shareholders of the date of the annual general meeting as and when appropriate.

### **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024, and will remain suspended pending the release of an announcement for the 2023 Annual Results. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

**The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.**

By Order of the Board  
**TATA Health International Holdings Limited**

Hong Kong, 27 June 2024

*As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.*